Clinical Trial · NCT05485792

18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer

Overview

FAP is overexpressed in the cancer-associated fibroblasts (CAFs) of 90% epithelial carcinomas. Currently, 68Ga-fibroblast activation protein inhibitor (FAPI) has shown promising diagnostic value in many types of tumors. However, there are currently no studies on head-to-head comparison of diagnosis value of various types of cancer in 18F-FAPI and 18F-FDG PET/CT. Therefore, we conducted a prospective study to investigate the value of 18F-FAPI PET/CT in various types of cancer, and compare it with 18F-FDG PET/CT.

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Phase

N/A

Contacts

Linqi Zhang, PhD (CONTACT)

zhanglinqi0909@163.com

0086-18825135918

Rusen Zhang, MD (CONTACT)

zhangrusen2015@163.com

0086-13642328295

Rusen Zhang, MD (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT05485792

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

FAPI

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Eligibility

Inclusion

patients who had scheduled both 18F-FAPI PET/CT and 18F-FDG PET/CT scans;
patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include CT, MRI and pathology report);

Exclusion

patients with non-malignant lesions;
patients with pregnancy;